Title:
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LEUKEMIA
Document Type and Number:
WIPO Patent Application WO/2019/143058
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition comprising a bromo domain inhibitor and cyclosporine A, or acceptable salts thereof as effective ingredients for prevention or treatment of cancer. The pharmaceutical composition can effectively induce cancer cells, preferably leukemia cells to undergo apoptosis, thus preventing or treating leukemia.
Inventors:
MIN YOO HONG (KR)
CHEONG JUNE WON (KR)
JANG JI EUN (KR)
EOM JU IN (KR)
JEUNG HOI KYUNG (KR)
CHEONG JUNE WON (KR)
JANG JI EUN (KR)
EOM JU IN (KR)
JEUNG HOI KYUNG (KR)
Application Number:
PCT/KR2019/000235
Publication Date:
July 25, 2019
Filing Date:
January 08, 2019
Export Citation:
Assignee:
UNIV YONSEI IACF (KR)
International Classes:
A61K38/13; A61K31/513; A61K45/06; A61P35/00; A61P35/02
Foreign References:
| KR20160027062A | 2016-03-09 | |||
| KR20150023562A | 2015-03-05 | |||
| KR20150023722A | 2015-03-05 |
Other References:
KURIMCHAK, ALISON M. ET AL.: "Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer", CELL REPORT, vol. 16, 2 August 2016 (2016-08-02), pages 1273 - 1286, XP055476391, doi:10.1016/j.celrep.2016.06.091
LIN, H-L ET AL.: "Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway", BRITISH JOURNAL OF CANCER, vol. 88, no. 6, 18 March 2003 (2003-03-18) - 24 March 2003 (2003-03-24), pages 973 - 980, XP055626150
LIN, H-L ET AL.: "Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway", BRITISH JOURNAL OF CANCER, vol. 88, no. 6, 18 March 2003 (2003-03-18) - 24 March 2003 (2003-03-24), pages 973 - 980, XP055626150
Attorney, Agent or Firm:
LEE, Jae Young (KR)
Download PDF: